| Massachusetts                   |   | 04-2652826          |
|---------------------------------|--------|---------------------|
| (State or Other Jurisdiction of |   | (I.R.S. Employer    |
| Incorporation or Organization)  |   | Identification No.) |

----

|                                                                                      | Page    |
|------------------------------------------------------------------------------------------------|---------|
| PART I - FINANCIAL INFORMATION                                                                 |    |
|                                                                                           |    |
| Item 1. Financial Statements (Unaudited)                                                       |    |
|  Consolidated Balance Sheets as of March 31, 2011 and December 31, 2010                   | 3       |
|                                                                                           |    |
|  Consolidated Statements of Operations for the Three Months Ended March 31, 2011 and 2010 | 4       |
|                                                                                           |    |
|  Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2011 and 2010 |  5 |
|                                                                                           |    |
|  Notes to Consolidated Financial Statements                                               | 6       |
|                                                                                           |    |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations  | 18      |
|                                                                                           |    |
| Item 4. Controls and Procedures                                                                | 25      |
|                                                                                           |    |
| PART II - OTHER INFORMATION                                                                    |    |
| Item 6. Exhibits                                                                               | 26      |

----

|                                                                                                                                                                                                                          |   | March 31,    |        |   | December 31, |         |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------------|-------------|--------|--------------|--------------|
| ASSETS                                                                                                                                                                                                                        |   | 2011         |        |   | 2010         |         |
| CURRENT ASSETS                                                                                                                                                                                                                |   |         |        |   |         |         |
| Cash and cash equivalents                                                                                                                                                                                                     |   | $            | 81,209      |   |         | $            | 552,849 |   |
| Restricted cash                                                                                                                                                                                                               |   |         | 20,012      |   |         |         | 20,014 |   |
| Accounts receivable                                                                                                                                                                                                           |   |         | 192,664     |   |         |         | 233,846 |   |
| Inventories                                                                                                                                                                                                                   |   |         | 1,140,270   |   |         |         | 1,104,056 |   |
| Deposits                                                                                                                                                                                                                      |   |         | 6,472       |   |         |         | 6,472 |   |
| Prepaid income taxes                                                                                                                                                                                                          |   |         | 3,639       |   |         |         | 1,442 |   |
| Prepaid expenses and other current assets                                                                                                                                                                                     |   |         | 346,725     |   |         |         | 296,756 |   |
| Total current assets                                                                                                                                                                                                          |   |         | 1,790,991   |   |         |         | 2,215,435 |   |
|                                                                                                                                                                                                                          |   |         |        |   |         |         |   |   |
| PROPERTY AND EQUIPMENT, NET                                                                                                                                                                                                   |   |         | 171,916     |   |         |         | 192,777 |   |
| OTHER ASSETS                                                                                                                                                                                                                  |   |         |        |   |         |         |   |   |
| Intangible assets, net                                                                                                                                                                                                        |   |         | 170,236     |   |         |         | 182,394 |   |
| TOTAL ASSETS                                                                                                                                                                                                                  |   | $            | 2,133,143   |   |         | $            | 2,590,606 |   |
|                                                                                                                                                                                                                          |   |         |        |   |         |         |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                                                                                                                                                          |   |         |        |   |         |         |   |   |
| CURRENT LIABILITIES                                                                                                                                                                                                           |   |         |        |   |         |         |   |   |
| Accounts payable                                                                                                                                                                                                              |   | $            | 528,355     |   |         | $            | 234,568 |   |
| Accrued employee compensation                                                                                                                                                                                                 |   |         | 226,104     |   |         |         | 172,251 |   |
| Accrued professional fees and other                                                                                                                                                                                           |   |         | 229,805     |   |         |         | 337,698 |   |
| Deferred revenue                                                                                                                                                                                                              |   |         | 30,804      |   |         |         | 27,153 |   |
| Total current liabilities                                                                                                                                                                                                     |   |         | 1,015,068   |   |         |         | 771,670 |   |
|                                                                                                                                                                                                                          |   |         |        |   |         |         |   |   |
| LONG TERM LIABILITIES                                                                                                                                                                                                         |   |         |        |   |         |         |   |   |
| Deferred revenue                                                                                                                                                                                                              |   |         | 10,042      |   |         |         | 9,427 |   |
| TOTAL LIABILITIES                                                                                                                                                                                                             |   |         | 1,025,110   |   |         |         | 781,097 |   |
|                                                                                                                                                                                                                          |   |         |        |   |         |         |   |   |
| COMMITMENTS AND CONTINGENCIES (Note 7)                                                                                                                                                                                        |   |         |        |   |         |         |   |   |
|                                                                                                                                                                                                                          |   |         |        |   |         |         |   |   |
| STOCKHOLDERS' EQUITY                                                                                                                                                                                                          |   |         |        |   |         |         |   |   |
| Series A Convertible Preferred Stock, $.01 par value; 1,000,000 shares authorized; 262,135 shares issued and outstanding on March 31, 2011 and on December 31, 2010 (Liquidation value of $3,014,553)                         |   |         |        |   |         |         |   |   |
|                                                                                                                                                                                                                          |   |  2,621  |        |   |         |  2,621  |   |   |
| Series B Convertible Preferred Stock, $.01 par value; 1,000,000 shares authorized; 85,509 and 88,711 shares issued and outstanding on March 31, 2011 and on December 31, 2010, respectively (Liquidation value of $1,607,569) |   |         |        |   |         |         |   |   |
|                                                                                                                                                                                                                          |   |  855    |        |   |         |  887    |   |   |
| Common stock, $.01 par value; 20,000,000 shares authorized; 2,850,975 and 2,711,750 shares issued and outstanding on March 31, 2011 and on December 31, 2010, respectively                                                    |   |         |        |   |         |         |   |   |
|                                                                                                                                                                                                                          |   |  28,510 |        |   |         |  27,118 |   |   |
| Warrants to acquire preferred stock and common stock                                                                                                                                                                          |   |         | 1,248,909   |   |         |         | 1,248,909 |   |
| Additional paid-in capital                                                                                                                                                                                                    |   |         | 12,282,840  |   |         |         | 12,095,237 |   |
| Accumulated deficit                                                                                                                                                                                                           |   |         | (12,455,702 | )      |         |         | (11,565,263 | ) |
| Total stockholders' equity                                                                                                                                                                                                    |   |         | 1,108,033   |   |         |         | 1,809,509 |   |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                                                                                                                                                                                    |   | $            | 2,133,143   |   |         | $            | 2,590,606 |   |

----

|                                                                                                          |   | For the Three Months Ended |      |
|---------------------------------------------------------------------------------------------------------------|--------|----------------------------|-----------|
|                                                                                                          |   | March 31,                  |      |
|                                                                                                          |   | 2011                       |      |   | 2010 |   |
|                                                                                                          |   |                       |      |   |   |   |
| REVENUE:                                                                                                      |   |                       |      |   |   |   |
| PCT Products, services, other                                                                                 |   | $                          | 180,643   |   |   | $ | 189,150 |   |
| Grant revenue                                                                                                 |   |                       | -         |   |   |   | 101,663 |   |
| Total revenue                                                                                                 |   |                       | 180,643   |   |   |   | 290,813 |   |
|                                                                                                          |   |                       |      |   |   |   |   |   |
| COSTS AND EXPENSES:                                                                                           |   |                       |      |   |   |   |   |   |
| Cost of PCT products and services                                                                             |   |                       | 78,929    |   |   |   | 87,103 |   |
| Research and development                                                                                      |   |                       | 218,965   |   |   |   | 294,141 |   |
| Selling and marketing                                                                                         |   |                       | 303,839   |   |   |   | 282,578 |   |
| General and administrative                                                                                    |   |                       | 412,529   |   |   |   | 538,422 |   |
| Total operating costs and expenses                                                                            |   |                       | 1,014,262 |   |   |   | 1,202,244 |   |
|                                                                                                          |   |                       |      |   |   |   |   |   |
| Operating loss                                                                                                |   |                       | (833,619  | ) |   |   | (911,431 | ) |
|                                                                                                          |   |                       |      |   |   |   |   |   |
| Interest income                                                                                               |   |                       | 254       |   |   |   | 106 |   |
| Net loss                                                                                                      |   |                       | (833,365  | ) |   |   | (911,325 | ) |
| Accrued and deemed dividends on convertible preferred stock                                                   |   |                       | (133,090  | ) |   |   | (256,524 | ) |
| Net loss applicable to common shareholders                                                                    |   | $                          | (966,455  | ) |   | $ | (1,167,849 | ) |
|                                                                                                          |   |                       |      |   |   |   |   |   |
|                                                                                                          |   |                       |      |   |   |   |   |   |
| Net loss per share attributable to common stockholders - basic and diluted                                    |   | $                          | (0.34     | ) |   | $ | (0.49 | ) |
|                                                                                                          |   |                       |      |   |   |   |   |   |
| Weighted average common stock shares outstanding used in the basic and diluted net loss per share calculation |   |                       | 2,836,971 |   |   |   | 2,394,311 |   |

----

|                                                                                      |   | For the Three Months Ended |     |
|-------------------------------------------------------------------------------------------|--------|----------------------------|----------|
|                                                                                      |   | March 31,                  |     |
|                                                                                      |   |                       |     |   |   |   |
|                                                                                      |   | 2011                       |     |   | 2010 |   |
| CASH FLOWS FROM OPERATING ACTIVITIES:                                                     |   |                       |     |   |   |   |
| Net loss                                                                                  |   | $                          | (833,365 | ) |   | $ | (911,325 | ) |
|                                                                                      |   |                       |     |   |   |   |   |   |
| Adjustments to reconcile net loss to operating cash flows:                                |   |                       |     |   |   |   |   |   |
| Depreciation and amortization                                                             |   |                       | 40,587   |   |   |   | 49,981 |   |
| Stock-based compensation expense                                                          |   |                       | 68,966   |   |   |   | 94,736 |   |
| Bad debt expense                                                                          |   |                       | -        |   |   |   | 8,620 |   |
|                                                                                      |   |                       |     |   |   |   |   |   |
| Changes in operating assets and liabilities:                                              |   |                       |     |   |   |   |   |   |
| Accounts receivable                                                                       |   |                       | 41,182   |   |   |   | (23,400 | ) |
| Inventories                                                                               |   |                       | (36,214  | ) |   |   | 62,217 |   |
| Deposits                                                                                  |   |                       | -        |   |   |   | (162,737 | ) |
| Accounts payable                                                                          |   |                       | 293,787  |   |   |   | 278,326 |   |
| Accrued employee compensation                                                             |   |                       | 53,853   |   |   |   | 47,503 |   |
| Deferred revenue and other accrued expenses                                               |   |                       | (84,682  | ) |   |   | (55,733 | ) |
| Prepaid expenses and other current assets                                                 |   |                       | (52,166  | ) |   |   | (7,684 | ) |
|         Net cash used in operating activities     |   |                       | (508,052 | ) |   |   | (619,496 | ) |
|                                                                                      |   |                       |     |   |   |   |   |   |
| CASH FLOWS FROM INVESTING ACTIVITIES:                                                     |   |                       |     |   |   |   |   |   |
| Additions to property and equipment                                                       |   |                       | (7,568   | ) |   |   | (30,060 | ) |
|         Net cash used in investing activities     |   |                       | (7,568   | ) |   |   | (30,060 | ) |
|                                                                                      |   |                       |     |   |   |   |   |   |
| CASH FLOWS FROM FINANCING ACTIVITIES:                                                     |   |                       |     |   |   |   |   |   |
| Proceeds from stock option exercise                                                       |   |                       | 43,980   |   |   |   | - |   |
| Proceeds from stock warrant exercise                                                      |   |                       | -        |   |   |   | 191,625 |   |
| Net proceeds from the issuance of preferred stock                                         |   |                       | -        |   |   |   | 465,867 |   |
|         Net cash provided by financing activities |   |                       | 43,980   |   |   |   | 657,492 |   |
|                                                                                      |   |                       |     |   |   |   |   |   |
| Change in cash and cash equivalents                                                       |   |                       | (471,640 | ) |   |   | 7,936 |   |
| Cash and cash equivalents, beginning of period                                            |   |                       | 552,849  |   |   |   | 1,609,778 |   |
| Cash and cash equivalents, end of period                                                  |   | $                          | 81,209   |   |   | $ | 1,617,714 |   |
|                                                                                      |   |                       |     |   |   |   |   |   |
| SUPPLEMENTAL INFORMATION:                                                                 |   |                       |     |   |   |   |   |   |
| Income taxes paid                                                                         |   | $                          | 1,900    |   |   | $ | 1,900 |   |
| Issuance of common stock dividend on preferred stock                                      |   |                       | 76,017   |   |   |   | 52,006 |   |
| Issuance of common stock warrants for services                                            |   |                       | -        |   |   |   | 18,122 |   |
| Beneficial conversion feature on convertible preferred stock                              |   |                       | -        |   |   |   | 154,389 |   |

----

| 1) | Business Overview and Management Plans |
|----|----------------------------------------|

| 2) | Interim Financial Reporting |
|----|-----------------------------|

| 3) | Summary of Significant Accounting Policies |
|----|--------------------------------------------|

----

----

|           |   | March 31, |      |   | December 31, |   |
|----------------|--------|-----------|-----------|--------|--------------|--------|
|           |   | 2011      |      |   | 2010         |   |
| Raw materials  |   | $         | 215,091   |   |         | $      | 198,534 |   |
| Finished goods |   |      | 925,179   |   |         |   | 905,522 |   |
| Total          |   | $         | 1,140,270 |   |         | $      | 1,104,056 |   |

|               |   | For the Three Months Ended |
|--------------------|--------|----------------------------|
|               |   | March 31,                  |
|               |   | 2011                       |   | 2010 |
| Top Five Customers | 55%    |                       | 78% |
| Federal Agencies   | 5%     |                       | 36% |

|               |   | March 31, |   | December 31, |
|--------------------|--------|-----------|--------|--------------|
|               |   | 2011      |   | 2010         |
| Top Five Customers | 60%    |      | 72%    |
| Federal Agencies   | 30%    |      | 29%    |

----

|                                                             |   | For the Three Months Ended |      |
|------------------------------------------------------------------|--------|----------------------------|-----------|
|                                                             |   | March 31,                  |      |
|                                                             |   | 2011                       |      |   | 2010 |   |
| Numerator:                                                       |   |                       |      |   |   |   |
| Net loss                                                         |   | $                          | (836,365  | ) |   | $ | (911,325 | ) |
| Accrued dividend for Series A and B Preferred Stock              |   |                       | (57,073   | ) |   |   | (50,129 | ) |
| Beneficial conversion feature for Series A and B Preferred Stock |   |                       | -         |   |   |   | (154,389 | ) |
| Series A Preferred dividends paid in Common Stock                |   |                       | (76,017   | ) |   |   | (44,963 | ) |
| Series B Preferred dividends paid in Common Stock                |   |                       | -         |   |   |   | (7,043 | ) |
| Net loss applicable to common shareholders                       |   | $                          | (969,455  | ) |   | $ | (1,167,849 | ) |
|                                                             |   |                       |      |   |   |   |   |   |
| Denominator for basic and diluted loss per share:                |   |                       |      |   |   |   |   |   |
| Weighted average common stock shares outstanding                 |   |                       | 2,836,971 |   |   |   | 2,394,311 |   |
|                                                             |   |                       |      |   |   |   |   |   |
| Loss per common share - basic and diluted                        |   | $                          | (0.34     | ) |   | $ | (0.49 | ) |

|                           | March 31,       |
|--------------------------------|-----------------|
|                           | 2011            |   | 2010 |
| Stock options                  |  1,114,500 |   |  1,019,500 |
| Common stock warrants          |  1,740,800 |   |  1,619,800 |
| Preferred stock warrants       |  940,550   |   |  2,025,770 |
| Convertible preferred stock:   |            |   |   |
| Series A Convertible Preferred |  2,621,350 |   |  1,744,400 |
| Series B Convertible Preferred |  855,090   |   |  887,110 |
|                           |  7,272,290 |   |  7,296,580 |

----

|                                   |   | For the Three Months Ended March 31, |   |
|----------------------------------------|--------|--------------------------------------|--------|
|                                   |   | 2011                                 |   |   | 2010 |   |
| Research and development               |   | $                                    | 21,604 |   |   | $ | 18,247 |   |
| Selling and marketing                  |   |                                 | 31,012 |   |   |   | 17,175 |   |
| General and administrative             |   |                                 | 16,350 |   |   |   | 59,314 |   |
| Total stock-based compensation expense |   | $                                    | 68,966 |   |   | $ | 94,736 |   |

| 4) | Commitments and Contingencies |
|----|-------------------------------|

----

| 5) | Stockholders’ Equity |
|----|----------------------------|

----

----

|                      |   |      |   |   |   |   |
|---------------------------|--------|-----------|--------|--------|--------|--------|
| Assumptions               |   | Preferred |   |   | Common |   |
| Expected life (in months) |   |      | 15.0   |   |   |   | 30.0 |   |
| Expected volatility       |   |      | 142.0  | %      |   |   | 109.0 | % |
| Risk-free interest rate   |   |      | 0.875  | %      |   |   | 1.375 | % |
| Exercise price            |   | $         | 1.25   |   |   | $      | 2.00 |   |
| Stock price               |   | $         | 0.90   |   |   | $      | 0.90 |   |
| Fair value per warrant    |   | $         | 0.45   |   |   | $      | 0.41 |   |

----

----

| Assumptions               |   | Preferred |   |   | Placement Agent |   |
|---------------------------|--------|-----------|--------|--------|-----------------|--------|
| Expected life (in months) |   |      | 17.0   |   |            |   | 33.0 |   |
| Expected volatility       |   |      | 146.4  | %      |            |   | 125.0 | % |
| Risk-free interest rate   |   |      | 1.000  | %      |            |   | 1.000 | % |
| Exercise price            |   | $         | 2.88   |   |            | $      | 2.88 |   |
| Fair value per warrant    |   | $         | 0.95   |   |            | $      | 1.08 |   |

----

|                                          |   | Stock Options |      |   | Warrants      |   |   |   |   |   |          |   |
|-----------------------------------------------|--------|---------------|-----------|--------|---------------|--------|--------|--------|--------|--------|---------------|--------|
|                                          |   |          |      |   | Weighted      |   |   |   |   |   | Weighted      |   |   |   |   |   |   |   |
|                                          |   |          |      |   | Average price |   |   |   |   |   | Average price |   |   | Total |   |   |   |   |
|                                          |   | Shares        |      |   | per share     |   |   | Shares |   |   | per share     |   |   | Shares |   |   | Exercisable |   |
| Balance outstanding, 12/31/2009               |   |          | 1,564,500 |   |          | $      | 2.52   |   |   |   | 3,806,640     |   |   | $ | 1.77 |   |   |   | 5,371,140 |   |   |   | 4,905,152 |   |
|       Granted   |   |          | 60,000    |   |          |   | 1.43   |   |   |   | 404,510       |   |   |   | 2.88 |   |   |   | 464,510 |   |   |   |   |   |
|       Exercised |   |          | (18,897   | )      |          |   | 1.07   |   |   |   | (1,529,800    | )      |   |   | 1.25 |   |   |   | (1,548,697 | ) |   |   |   |   |
|       Expired   |   |          | -         |   |          |   | -      |   |   |   | -             |   |   |   | - |   |   |   | - |   |   |   |   |   |
|       Forfeited |   |          | -         |   |          |   | -      |   |   |   | -             |   |   |   | - |   |   |   | - |   |   |   |   |   |
| Balance outstanding, 12/31/2010               |   |          | 1,605,603 |   |          | $      | 2.49   |   |   |   | 2,681,350     |   |   | $ | 2.24 |   |   |   | 4,286,953 |   |   |   | 4,114,792 |   |
|       Granted   |   |          | -         |   |          |   | -      |   |   |   | -             |   |   |   | - |   |   |   | - |   |   |   |   |   |
|       Exercised |   |          | (41,103   | )      |          |   | 1.07   |   |   |   | -             |   |   |   | - |   |   |   | (41,103 | ) |   |   |   |   |
|       Expired   |   |          | -         |   |          |   | -      |   |   |   | -             |   |   |   | - |   |   |   | - |   |   |   |   |   |
|       Forfeited |   |          | -         |   |          |   | -      |   |   |   | -             |   |   |   | - |   |   |   | - |   |   |   |   |   |
| Balance outstanding, 3/31/2011                |   |          | 1,564,500 |   |          | $      | 2.53   |   |   |   | 2,681,350     |   |   | $ | 2.24 |   |   |   | 4,245,850 |   |   |   | 4,197,683 |   |

|                     |   |   |              |   |   |                       |   |   | Options Outstanding |   |   | Options Exercisable |      |
|--------------------------|--------|--------|-------------------|--------|--------|----------------------------|--------|--------|---------------------|--------|--------|---------------------|-----------|
|                     |   |   |              |   |   |                       |   |   |                |   |   | Weighted Average    |      |   |   |   |   | Weighted Average |   |
| Range of Exercise Prices |   |   | Number of Options |   |   | Remaining Contractual Life |   |   | Exercise Price      |   |   | Number of Options   |      |   | Remaining Contractual Life |   |   | Exercise Price |   |
| $                        | 0.77   |   |              |   | -      |                       |   | $      | 2.70                |   |   |                | 704,000   |   |   |   | 6.3 |   |   | $ | 1.28 |   |   |   | 674,000 |   |   |   | 6.2 |   |   | $ | 1.27 |   |
|                     | 2.71   |   |              |   | -      |                       |   |   | 3.08                |   |   |                | 319,500   |   |   |   | 3.8 |   |   |   | 2.93 |   |   |   | 301,333 |   |   |   | 3.5 |   |   |   | 2.94 |   |
|                     | 3.09   |   |              |   | -      |                       |   |   | 3.95                |   |   |                | 302,000   |   |   |   | 5.2 |   |   |   | 3.67 |   |   |   | 302,000 |   |   |   | 5.2 |   |   |   | 3.67 |   |
|                     | 3.96   |   |              |   | -      |                       |   |   | 5.93                |   |   |                | 239,000   |   |   |   | 5.0 |   |   |   | 4.24 |   |   |   | 239,000 |   |   |   | 5.0 |   |   |   | 4.24 |   |
| $                        | 0.77   |   |              |   | -      |                       |   | $      | 5.93                |   |   |                | 1,564,500 |   |   |   | 5.4 |   |   | $ | 2.53 |   |   |   | 1,516,333 |   |   |   | 5.3 |   |   | $ | 2.55 |   |

----

| 6) | Subsequent Events |
|----|-------------------|

----

| -  | our ability to raise additional equity or debt financing on acceptable terms, if at all;                                                                                                                                         |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| -  | our belief that we have sufficient liquidity to finance normal operations through the second quarter of 2011;                                                                                                                    |
| -  | our need to take additional cost reduction measures, cease operations or sell our operating assets, if we are unable to obtain sufficient additional financing in the future;                                                    |
| -  | the amount of cash necessary to operate our business;                                                                                                                                                                            |
| -  | the amount of grant revenue and anticipated uses of grant revenue in future periods;                                                                                                                                             |
| -  | our plans and expectations with respect to our pressure cycling technology (PCT) operations;                                                                                                                                     |
| -  | the potential applications for PCT in, and the demonstration of proof-of-concept of PCT for, sample preparation, pathogen inactivation, protein purification, control of chemical reactions and immunodiagnostics, among others; |
| -  | the expected expenses, benefits and results from our research and development efforts;                                                                                                                                           |
| -  | the expected benefits and results from our collaboration efforts;                                                                                                                                                                |
| -  | the expected increase in number of PCT units installed and the increase in revenues from sale of consumable products and extended service contracts;                                                                             |
| -  | the potential size of the market for biological sample preparation;                                                                                                                                                              |
| -  | general economic conditions; and                                                                                                                                                                                                 |
| -  | the anticipated future financial performance and business operations of our Company.                                                                                                                                             |

----

----

| - | sample preparation for genomic, proteomic, and small molecule studies; |
|---|------------------------------------------------------------------------|
| - | pathogen inactivation;                                                 |
| - | protein purification;                                                  |
| - | control of chemical (particularly enzymatic) reactions; and            |
| - | Immunodiagnostics (clinical laboratory testing).                       |

|            | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | Q1 2011 |
|-----------------|------|------|------|------|------|------|---------|
| Installed units | 5    | 8    | 20   | 41   | 54   | 50   | 10      |

----

|                           |     |   |     | For the Three Months Ended |
|--------------------------------|----------|--------|----------|----------------------------|
|                           |     |   |     | March 31,                  |   |
|                           |     |   |     | 2011                       |   | 2010 |   |
| Domestic                       |     |   |  8  |                       |  10 |   |
| International                  |     |   |  2  |                       |  - |   |
| Total PCT System Installations |  10 |   |  10 |                       |

----

----

----

----

----

| Exhibits |                                                                                                                                                          |   | Reference      |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|----------------|
|     |                                                                                                                                                          |   |           |
| 31.1     | Principal Executive Officer Certification Pursuant to Item 601(b)(31) of Regulation S-K, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |   | Filed herewith |
|     |                                                                                                                                                          |   |           |
| 32.1     | Principal Executive Officer Certification Pursuant to Item 601(b)(32) of Regulation S-K, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |   | Filed herewith |

----

|               |                                                                                                                                                          |                     |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------|
|               | PRESSURE BIOSCIENCES, INC.                                                                                                                                    |
|               |                                                                                                                                                          |                     |
| Date: May 16, 2011 | By:                                                                                                                                                 | /s/Richard T. Schumacher |
|               |  Richard T. SchumacherPresident & Chief Executive Officer(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer) |
|               |                                                                                                                                                          |

|   |   |   |
|--------|--------|--------|
|   |   |